Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3921 (Unasnemab) in Acute Spinal Cord Injury
NCT04096950Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Apr 2020
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of unasnemab in spinal cord injury (SCI), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Percentage of subjects with adverse events at 6 months. Started Apr 2020; status: completed.
02
Drugs
unasnemab
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT04096950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04096950.